Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from HFSA Out Now!
2023 | HFSA

New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes

Industry News In The News

Oak Ridge, TN – May 18, 2023 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure patients published in the European Society of Cardiology Heart Failure.  The results of the study demonstrated Daxor’s blood volume analysis (BVA) provides unique and individualized data that is critical for targeting heart failure therapy and is predictive of clinical outcomes.

The study titled, “Differences in Red Blood Cell Mass Profiles Impact Intravascular Volume and Outcome Risk in Chronic Heart Failure,” studied the differences in total blood volume and red blood cell mass – two critical treatment targets in patients who were considered clinically stable and their impact on clinical outcomes in chronic heart failure. Both measures were determined using Daxor’s innovative BVA technology. The results showed that survival rates of patients could be predicted with blood volume analysis via Daxor’s test from their red blood cell levels. 

Wayne L. Miller, M.D., Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, lead author of the study, concluded, “The findings of this study demonstrate that patients with chronic heart failure develop marked differences in profiles despite comparable stable clinical status, and that this variability has significant associations with the important clinical outcomes of heart failure-related mortality and hospitalizations.”